| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
|
J Clin Oncol
|
2005
|
8.08
|
|
2
|
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
|
J Clin Oncol
|
2006
|
6.95
|
|
3
|
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
|
Clin Cancer Res
|
2007
|
5.36
|
|
4
|
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
|
J Clin Oncol
|
2005
|
4.99
|
|
5
|
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
|
Clin Cancer Res
|
2003
|
4.55
|
|
6
|
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.
|
Ann Surg
|
2008
|
3.16
|
|
7
|
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
|
J Clin Oncol
|
2006
|
3.00
|
|
8
|
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
|
J Clin Oncol
|
2005
|
2.75
|
|
9
|
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.
|
J Clin Oncol
|
2010
|
2.51
|
|
10
|
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
|
Clin Cancer Res
|
2007
|
2.50
|
|
11
|
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
|
Clin Cancer Res
|
2005
|
1.97
|
|
12
|
The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS).
|
IEEE Trans Med Imaging
|
2014
|
1.91
|
|
13
|
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases.
|
Ann Surg
|
2008
|
1.85
|
|
14
|
Lung endothelial heparan sulfates mediate cationic peptide-induced barrier dysfunction: a new role for the glycocalyx.
|
Am J Physiol Lung Cell Mol Physiol
|
2003
|
1.76
|
|
15
|
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
|
J Clin Oncol
|
2005
|
1.73
|
|
16
|
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
|
Oncology
|
2011
|
1.61
|
|
17
|
Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
|
J Clin Oncol
|
2004
|
1.58
|
|
18
|
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
|
Urology
|
2002
|
1.57
|
|
19
|
Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter.
|
Ann Allergy Asthma Immunol
|
2010
|
1.55
|
|
20
|
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse.
|
Clin Prostate Cancer
|
2004
|
1.55
|
|
21
|
Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction.
|
Arch Surg
|
2010
|
1.52
|
|
22
|
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
|
Invest New Drugs
|
2006
|
1.46
|
|
23
|
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
|
Cancer
|
2004
|
1.45
|
|
24
|
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
|
J Clin Oncol
|
2009
|
1.36
|
|
25
|
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker.
|
Acad Radiol
|
2010
|
1.35
|
|
26
|
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
|
Clin Lung Cancer
|
2006
|
1.21
|
|
27
|
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
|
Clin Cancer Res
|
2007
|
1.20
|
|
28
|
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
|
Clin Cancer Res
|
2005
|
1.17
|
|
29
|
The use of volumetric CT as an imaging biomarker in lung cancer.
|
Acad Radiol
|
2010
|
1.15
|
|
30
|
Gemcitabine-related radiation recall preferentially involves internal tissue and organs.
|
Cancer
|
2004
|
1.10
|
|
31
|
Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population.
|
Abdom Imaging
|
2011
|
1.10
|
|
32
|
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
|
Clin Cancer Res
|
2009
|
1.08
|
|
33
|
Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis.
|
Infect Immun
|
2007
|
1.00
|
|
34
|
Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies.
|
Ann Surg Oncol
|
2012
|
0.99
|
|
35
|
Hepatic intraductal oncocytic papillary carcinoma.
|
Cancer
|
2002
|
0.98
|
|
36
|
The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas.
|
J Gastrointest Surg
|
2006
|
0.95
|
|
37
|
Future vision for the quality assurance of oncology clinical trials.
|
Front Oncol
|
2013
|
0.93
|
|
38
|
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
|
Cancer
|
2003
|
0.91
|
|
39
|
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
|
Invest New Drugs
|
2007
|
0.91
|
|
40
|
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.
|
Invest New Drugs
|
2002
|
0.90
|
|
41
|
IL-4 and TGF-beta 1 counterbalance one another while regulating mast cell homeostasis.
|
J Immunol
|
2010
|
0.90
|
|
42
|
Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
|
Thromb Haemost
|
2012
|
0.90
|
|
43
|
Automated framework for digital radiation dose index reporting from CT dose reports.
|
AJR Am J Roentgenol
|
2011
|
0.89
|
|
44
|
Granular packings: nonlinear elasticity, sound propagation, and collective relaxation dynamics.
|
Phys Rev E Stat Nonlin Soft Matter Phys
|
2004
|
0.89
|
|
45
|
Kinetics of liver volume changes in the first year after portal vein embolization.
|
Arch Surg
|
2010
|
0.88
|
|
46
|
Gemcitabine-induced pulmonary toxicity.
|
Anticancer Res
|
2012
|
0.86
|
|
47
|
Cuffed endotracheal tubes in infants and children: should we routinely measure the cuff pressure?
|
Int J Pediatr Otorhinolaryngol
|
2011
|
0.86
|
|
48
|
Imaging of neuroendocrine tumors.
|
Semin Oncol
|
2013
|
0.85
|
|
49
|
Anesthetic management of the hybrid stage 1 procedure for hypoplastic left heart syndrome (HLHS).
|
Paediatr Anaesth
|
2010
|
0.84
|
|
50
|
Liver regeneration in humans is characterized by significant changes in cellular phosphorus metabolism: assessment using proton-decoupled 31P-magnetic resonance spectroscopic imaging.
|
Magn Reson Med
|
2005
|
0.82
|
|
51
|
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
|
Clin Cancer Res
|
2003
|
0.82
|
|
52
|
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.
|
J Allergy Clin Immunol
|
2011
|
0.81
|
|
53
|
Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
|
J Surg Oncol
|
2005
|
0.81
|
|
54
|
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
|
Invest New Drugs
|
2004
|
0.77
|
|
55
|
Syk deficiency in human non-releaser lung mast cells.
|
Clin Immunol
|
2007
|
0.77
|
|
56
|
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.
|
Gastrointest Cancer Res
|
2012
|
0.77
|
|
57
|
Imaging approaches with advanced prostate cancer: techniques and timing.
|
Can J Urol
|
2014
|
0.76
|
|
58
|
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma.
|
Clin Genitourin Cancer
|
2008
|
0.75
|
|
59
|
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.
|
Urology
|
2002
|
0.75
|
|
60
|
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
|
J Surg Oncol
|
2004
|
0.75
|
|
61
|
Study month or vacation? Preparing for USMLE Step 2.
|
Acad Med
|
2002
|
0.75
|